The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pleural Effusion Differential Diagnosis

Systematic approach to identifying the cause of fluid accumulation in pleural space using Light criteria (1972) for transudate vs exudate distinction, followed by directed workup based on biochemistry, cytology, microbiology, and imaging; differential includes congestive heart failure (most common cause), pneumonia, malignancy, tuberculosis, pulmonary embolism, autoimmune disease.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Pleural Effusion Differential Diagnosis?

Pleural effusion is the abnormal accumulation of fluid in the pleural space, between the visceral and parietal pleural membranes. Normal pleural fluid is 5-15 mL, formed continuously from parietal pleura capillaries (filtration) and absorbed by parietal pleura lymphatics (Stoma); imbalance in formation or absorption leads to effusion.

Pathophysiology: 1) Increased hydrostatic pressure (congestive heart failure — most common transudative cause); 2) Decreased oncotic pressure (hypoalbuminemia in cirrhosis, nephrotic syndrome, malnutrition); 3) Increased capillary permeability (inflammation, infection, malignancy — exudative); 4) Lymphatic obstruction (mediastinal lymphadenopathy, malignancy, fibrosing mediastinitis); 5) Diaphragmatic disruption (peritoneal-pleural communication in cirrhosis with hepatic hydrothorax); 6) Hemothorax (trauma, malignancy, anticoagulation); 7) Chylothorax (thoracic duct disruption); 8) Empyema (infected pleural fluid).

Classification by Light criteria (1972, modified): Transudate — pleural fluid protein/serum protein < 0.5 AND pleural fluid LDH/serum LDH < 0.6 AND pleural fluid LDH < 2/3 upper normal serum LDH (e.g. < 200 IU/L); Exudate — meets any one of: pleural fluid protein/serum protein > 0.5, pleural fluid LDH/serum LDH > 0.6, pleural fluid LDH > 2/3 upper limit normal serum LDH; Light criteria sensitivity 98 percent for exudate, specificity 80 percent (10-15 percent of CHF on diuretics misclassified as exudate — use serum-pleural fluid albumin gradient > 1.2 g/dL to confirm transudate). Etiologies of transudate: congestive heart failure 90 percent, cirrhosis with hepatic hydrothorax, nephrotic syndrome, peritoneal dialysis, hypoalbuminemia, atelectasis, urinothorax, central venous catheter migration. Etiologies of exudate: parapneumonic 50 percent, malignancy 25 percent, pulmonary embolism 5-10 percent, tuberculosis (4-15 percent globally, < 1 percent in developed nations), connective tissue diseases (rheumatoid, lupus), pancreatitis, esophageal rupture, hemothorax, chylothorax, drug-induced, post-CABG, asbestos exposure (benign asbestos pleural effusion, mesothelioma).

Symptoms

Dyspnea on exertion progressing to rest dyspnea (most common symptom)
Dry cough (pleural irritation)
Pleuritic chest pain (worse with deep breathing — suggests inflammatory cause)
Decreased breath sounds at base (collapsed lung beneath effusion)
Dullness to percussion at base (Stony dull)
Decreased tactile fremitus over effusion
Egophony at upper border of effusion ('E' to 'A' transition)
Tracheal deviation away from large effusion
Constitutional symptoms (fever, weight loss, night sweats — TB or malignancy)
Symptoms of underlying disease (CHF — orthopnea, edema; pneumonia — fever, productive cough; malignancy — weight loss, anorexia, smoker history)

Risk Factors

Heart failure (chronic CHF most common cause of transudate)
Pneumonia (parapneumonic effusion, may progress to empyema 5-10 percent)
Malignancy (lung cancer, breast cancer, lymphoma, mesothelioma) — 50 percent of all malignant effusions are lung cancer
Tuberculosis (high prevalence in resource-limited settings, immunocompromised)
Pulmonary embolism (often bloody small effusion)
Cirrhosis with portal hypertension (hepatic hydrothorax)
Nephrotic syndrome (hypoalbuminemia)
Asbestos exposure (benign and malignant pleural disease 20-40 year latency)
Recent surgery (CABG, lung resection)
Trauma (hemothorax)
Drug-induced (amiodarone, nitrofurantoin, methotrexate, ergot derivatives, beta-blockers, dasatinib)
Connective tissue disease (lupus pleuritis 50 percent of SLE patients, rheumatoid arthritis)
Pancreatitis (acute or chronic — left-sided exudate with elevated amylase)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Progressive dyspnea, especially with exertion or lying flat
  • Chest pain with breathing (pleuritic)
  • Persistent cough lasting more than 3 weeks
  • Constitutional symptoms (unexplained fever, night sweats, weight loss)
  • History of cancer with new shortness of breath
  • History of heart failure with worsening symptoms
  • Recent pneumonia with persistent shortness of breath
  • History of asbestos exposure (industrial worker, military)
  • History of tuberculosis or recent TB exposure

Treatment Methods

01
Initial evaluation: detailed history (dyspnea, chest pain, cough, fever, weight loss, occupational exposures asbestos, smoking, prior cancer, heart failure history, drug history), physical examination (respiratory rate, oxygen saturation, JVP elevation in CHF, peripheral edema, lymphadenopathy, thyroid examination, breast examination in women, lung exam findings), vital signs
02
Imaging: 1) Chest X-ray (PA and lateral) — visible effusion if > 200 mL on PA, > 50 mL on lateral; bilateral effusions suggest CHF, drugs, malignancy; massive unilateral effusion suggests malignancy or empyema; 2) Lung ultrasound (POCUS) — detects effusion as small as 5-10 mL, confirms anechoic fluid (transudate) vs complex septated (empyema, hemothorax), guides safe thoracentesis (5-10 cm depth, no ribs, no diaphragm); 3) CT chest — characterizes pleural thickening (mesothelioma, metastatic), nodularity, mediastinal lymphadenopathy, parenchymal disease; 4) PET-CT — distinguishes benign vs malignant pleural disease
03
Diagnostic thoracentesis: indicated for new effusion of unknown etiology > 10 mm on lateral decubitus X-ray (or echo-guided ultrasound criteria); ultrasound-guided procedure (decreased complications), local anesthesia (lidocaine), 18-22 G needle, 60 mL syringe; aspirate 50-100 mL diagnostic, up to 1.5 L therapeutic in single session (avoid > 1.5 L to prevent re-expansion pulmonary edema); routine fluid analysis: appearance (clear straw — transudate, turbid — empyema, bloody — malignancy/PE/trauma, milky — chylous), pH (< 7.2 = complicated parapneumonic effusion needing drainage), protein, LDH, glucose (low in empyema, RA, TB, malignancy), cell count and differential (neutrophils — bacterial; lymphocytes — TB, lymphoma, malignancy; eosinophils — drug, asbestos, pneumothorax, fungal), Gram stain and culture, cytology (3 separate samples increases yield), AFB stain and culture if TB suspected
04
Light criteria application: classify as transudate or exudate; if transudate — workup CHF (echocardiogram, BNP), cirrhosis (LFTs, ultrasound), nephrotic syndrome (urinalysis, albumin); treat underlying cause; if exudate — proceed with extensive workup
05
Specific tests for exudates based on suspicion: 1) Tuberculosis workup — pleural fluid adenosine deaminase (ADA > 40 U/L sensitivity 90 percent specificity 89 percent for TB), interferon-gamma release assays (IGRA, ELISpot, QuantiFERON), AFB smear (low yield), AFB culture (40-60 percent yield, 6-8 weeks), biopsy (granulomas with caseating necrosis, AFB positive 60-80 percent); 2) Malignancy workup — fluid cytology (sensitivity 60 percent first sample, 80 percent three samples), pleural biopsy (closed needle Abrams 40 percent yield, image-guided needle biopsy 80-90 percent), thoracoscopy (90-95 percent yield); 3) Pulmonary embolism — CT pulmonary angiography, D-dimer; 4) Pancreatitis — pleural fluid amylase elevated; 5) Esophageal rupture — pleural fluid amylase salivary, low pH, food particles; 6) Chylothorax — triglycerides > 110 mg/dL, chylomicrons; 7) Hemothorax — hematocrit > 50 percent of serum
06
Therapeutic procedures: 1) Therapeutic thoracentesis — relieve dyspnea, up to 1.5 L per session; 2) Tube thoracostomy (chest tube drainage) — for parapneumonic effusion with pH < 7.2 or empyema, hemothorax, large recurrent effusions; 24-32 F large bore for empyema, 12-16 F for simple effusion; 3) Intrapleural fibrinolytics (tPA + DNase per MIST2 trial 2011) — for complex parapneumonic effusion or early empyema, improves drainage compared to placebo; 4) Video-assisted thoracoscopic surgery (VATS) — for empyema not responding to drainage and antibiotics, biopsy of pleural disease, pleurodesis for recurrent malignant effusions; 5) Indwelling pleural catheter (PleurX) — for recurrent malignant pleural effusions with poor performance status, allows home drainage 2-3 times weekly, talc pleurodesis at home in 70 percent achieve spontaneous pleurodesis within 2 months
07
Treatment of underlying cause: CHF — diuretics, optimize heart failure regimen; cirrhosis — diuretics (spironolactone + furosemide), low salt diet, TIPS for refractory; pneumonia — appropriate antibiotics (covering Streptococcus pneumoniae, Staphylococcus aureus, anaerobes; broad-spectrum if hospital-acquired); malignancy — chemotherapy/targeted therapy/immunotherapy directed at primary cancer; TB — 4-drug regimen (RIPE: rifampin, isoniazid, pyrazinamide, ethambutol) for 2 months then 4 months RI; PE — anticoagulation (DOAC or warfarin); pancreatitis — supportive, ERCP if biliary; lupus — corticosteroids, hydroxychloroquine; rheumatoid — methotrexate, biologics
08
Pleurodesis options for recurrent malignant or benign effusions: 1) Talc poudrage (during thoracoscopy, 4-5 g) — most effective, 70-90 percent successful; 2) Talc slurry (via chest tube, 4-5 g in 50 mL saline) — outpatient procedure, 60-80 percent successful; 3) Indwelling pleural catheter (alternative to pleurodesis); 4) Surgical pleurectomy/decortication (rare, for refractory empyema or trapped lung)
09
Complications of pleural procedures: pneumothorax 5-10 percent (decreased with ultrasound guidance to 1-2 percent), bleeding (intercostal artery injury, hemothorax), re-expansion pulmonary edema (rare, < 1 percent if drainage limited to 1.5 L), infection (low risk), chest tube blockage, pleural fluid loculations requiring fibrinolytics or VATS, vasovagal reaction, pleural pain, scarring, secondary spontaneous pneumothorax
10
Follow-up: chest X-ray after thoracentesis to assess re-accumulation, monitor underlying disease treatment response, repeat thoracentesis or pleural biopsy if undiagnosed exudate persists; prognosis depends on underlying cause — CHF effusion improves with diuretics, malignant effusion median survival 4-6 months from diagnosis, TB effusion excellent with 6-month treatment

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.